This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jan;8(1):1.

doi: 10.1038/nrurol.2010.211.

Prostate cancer: A rocky road to overcoming castration resistance

Suzanne J Farley

PMID: 21287696
DOI: 10.1038/nrurol.2010.211

Comment

Prostate cancer: A rocky road to overcoming castration resistance

Suzanne J Farley. Nat Rev Urol. 2011 Jan.

. 2011 Jan;8(1):1.

doi: 10.1038/nrurol.2010.211.

Author

Suzanne J Farley

PMID: 21287696
DOI: 10.1038/nrurol.2010.211

No abstract available

PubMed Disclaimer

Comment on

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. James ND, et al. BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x. BJU Int. 2010. PMID: 20840318 Clinical Trial.

References

1. BJU Int. 2010 Oct;106(7):966-73 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.